Fig. 1




C1
N2
N1
C4
C2
C5
C6
C3
Cl1
C8C7
N3
C9
N4
C10
OOAA
N5
C11
N6
C12
C13
C14
C15
F1
C16
F2
C17
C18
F3
O2
C19
C20
C23
C22
N7
C24
C21
S1
O3
O5
O4
C30
C25
C26
C28
C29
C31
C27

Fig. 2

Fig. 3




O38_a
C23_a
O39_a
C24_a
C24
C23
O38
O39
C1
N9
N1
C4
C5
C2
C3
C6
CL36
C8
C7
N10
N16
C9
F31
C17
C18
F33
C16
C13
C12
N12
C10
O34
C15
C14
C11
N14
F32
O35
C19
N23
N22
C20
N20
C22
C21
O43_b
C25_b
C26_b
O41_b
C26
C25
O41
O43

Fig. 4

Fig. 5A



* P<0.05, ** P<0.001, *** P<0.0001 vs vehicle (dunnett's method)

Fig. 5B



* P<0.05, ** P<0.001, *** P<0.0001 vs vehicle (dunnett's method)

Fig. 6A


Administration after day 1 of infection
Virus titers ($log_{10}TCID_{50}$/mL)
8
7
6
5
4
3
2
1
1
2
3
Days post-infection
Vehicle
Compound of present invention 30 mg/kg
Compound of present invention 150 mg/kg

Fig. 6B


Administration after day 3 of infection
Virus titers ($log_{10}TCID_{50}$/mL)
8
7
6
5
4
3
2
1
1
2
3
4
5
Days post-infection
Vehicle
Compound of present invention 30 mg/kg
Compound of present invention 150 mg/kg

Fig. 7


tid
Virus titers ($log_{10}TCID_{50}$/mL)
7
6
5
4
3
2
1
1
2
3
Days post-infection
**
***
***
***
***
***
Vehicle (bid for 2 days)
8 mg/kg (tid for 2 days)
16 mg/kg (tid for 2 days)
32 mg/kg (tid for 2 days)
64 mg/kg (tid for 2 days)

Fig. 8A


Retired, TY7-501 body weight (%)
1×10^5 TCID50_Vehicle
1×10^5 TCID50_compound of present invention
105%
100%
95%
90%
85%
80%
75%
70%
-1
0
1
2
3
4
5
6
7

Fig. 8B


Retired, TY7-501 survival rate (%)
1×10^5 TCID50_Vehicle
1×10^5 TCID50_compound of present invention
100%
80%
60%
40%
20%
0%
-1
0
1
2
3
4
5
6
7

Fig. 8C


15-week-old, MA-P10 body weight (%)
1×10^3 TCID50_Vehicle
1×10^3 TCID50_compound of present invention
1×10^4 TCID50_Vehicle
1×10^4 TCID50_compound of present invention
115%
110%
105%
100%
95%
90%
85%
80%
75%
70%
-1
0
1
2
3
4
5
6
7

Fig. 8D


15-week-old, MA-P10 survival rate (%)
1×10^3 TCID50_Vehicle
1×10^3 TCID50_compound of present invention
1×10^4 TCID50_Vehicle
1×10^4 TCID50_compound of present invention
100%
80%
60%
40%
20%
0%
-1
0
1
2
3
4
5
6
7

Fig. 8E


Retired, MA-P10 body weight (%)
1×10^3 TCID50_Vehicle
1×10^3 TCID50_compound of present invention
110%
105%
100%
95%
90%
85%
80%
75%
70%
-1
0
1
2
3
4
5
6
7

Fig. 8F


Retired, MA-P10 survival rate (%)
1×10^3 TCID50_Vehicle
1×10^3 TCID50_compound of present invention
100%
80%
60%
40%
20%
0%
-1
0
1
2
3
4
5
6
7

Fig. 9



Fumaric acid cocrystal Form I crystal of compound represented by Formula (I-B) (bid)

Fig. 10



Fumaric acid cocrystal Form I crystal of compound represented by Formula (I-B) (BID)

Fumaric acid cocrystal Form I crystal of compound represented by Formula (I-B) (BID)

Fig. 11A



Fumaric acid cocrystal Form I crystal of compound represented by Formula (I-B) (BID)

Fig. 11B



Fumaric acid cocrystal Form I crystal of compound represented by Formula (I-B) (BID)

Fig. 12A



Fig. 12B